YR
Therapeutic Areas
Harbour BioMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Batoclimab (HBM9161) | Myasthenia Gravis | Phase 3 |
| HBM9378 (SKB378/WIN378) | Asthma, COPD | Phase 1 |
| HBM7575 (SKB575) | Atopic Dermatitis | IND Filed |
| HBM2001 | Inflammatory Bowel Disease (IBD) | Discovery |
| J9003 | IBD | Discovery |
| R1065 | IgA Nephropathy (IgAN) | Discovery |
| OX40L Family | Dermatosis | Discovery |
| HBM7020 | Autoimmune Diseases | Discovery |
Leadership Team at Harbour BioMed
JW
Jingsong Wang
Founder, Chairman & Chief Executive Officer
JX
Jenny Xie
Chief Scientific Officer, Immunology and Head of Global External Innovation
XT
Xiaolu Tao
President of Harbour Therapeutics
RZ
Raymond Zheng
Chief Business Officer
MD
Michael D. Patten
Chief Strategy Officer
BC
Ben Chih
Chief Scientific Officer - Neurosciences, Entrepreneur in Residence, Harbour BioMed US
YC
Youchen Chen
Chief Financial Officer
IY
Ian Y. Liu
Senior Vice President, Global Head of Business Development & Licensing